CTOs on the Move

Context Therapeutics

www.contexttherapeutics.com

 
Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Armstrong Pharmaceuticals Inc

Armstrong Pharmaceuticals, Inc. was founded in 1955 as a manufacturer of specialty aerosol products. Armstrong produced a wide array of topical, personal care, and pharmaceutical products. Since 1993, Armstrong has focused exclusively on pharmaceutical

ST CATHRINE REGINAL HOSP

ST CATHRINE REGINAL HOSP is a Charlestown, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verena Solutions

Verena Solutions is revolutionizing the dental field through an array of hardware, products, and services that advance the delivery of care.

Dragon Pharmaceuticals

Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in China, Egypt, India and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East.